Xtandi for prostate cancer – pro
It is in a clincal study: Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers, NCT02749903. LO HO reported a phase II trial evaluated the anti-androgen enzalumatide (Astellas). There was failure to meet the protocol-defined measure of success was due in part to the lack of durability of initial responses. The treatmetn is still E/I and cannot be said to offer a clear benefit that outweighs risks.
Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head Neck. 2018;40(3):605-613. doi:10.1002/hed.25035
Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.
Alan Loh Ho, Nathan R. Foster, Alexander J. Zoroufy, Francis P. Worden, Katharine Andress Rowe Price, Douglas Adkins, Daniel W. Bowles, Hyunseok Kang, Barbara Burtness, Eric Jeffrey Sherman, Roscoe F. Morton, Nora Katabi, Pamela N. Munster, and Gary K. Schwartz
Journal of Clinical Oncology 2019 37:15_suppl, 6020-6020